Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants

NCT02510560 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

300

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Premature Birth of Newborn
Intestinal Malabsorption

Interventions

DRUG: NTRA-2112
DRUG: Placebo

Sponsor

Elgan Pharma Ltd.